Zydus Life Share Price Surges Up to 7%, Hitting 52-Week High on Robust Q4 Earnings

Zydus Lifesciences Surges to 52-Week High After Strong Earnings

Zydus Lifesciences, a leading pharmaceutical company, has seen a significant surge in its stock price, hitting a 52-week high of Rs 1,093.65 per share. This represents a gain of over 7% and marks the company's highest level in more than one year. The impressive performance comes on the back of a healthy set of earnings for the quarter ended March, which exceeded market expectations.

The company's profit, when adjusted for a one-time payment made to settle the patent for Mirabegron, demonstrated a strong financial performance. This adjustment allowed the company's profit to surpass the Street's estimates, further solidifying investor confidence.

Looking ahead, the management has provided a positive outlook for the company's financial performance. Zydus Lifesciences has guided for its earnings before interest, taxes, depreciation, and amortisation (EBITDA) to grow by over 24% in the fiscal year 2026-27 (April-March). The company also expects its US sales to grow in single digits in FY27, despite facing competitive intensity in the market.

Read also: Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4

Brokerages have largely retained their positive outlook on the company, with many raising their target prices in response to the strong earnings performance. This renewed optimism is expected to drive further growth in the company's stock price, making it an attractive investment opportunity for investors.